| scholarly article | Q13442814 |
| P50 | author | Ian Andrew Wilson | Q5983280 |
| Dennis R. Burton | Q56331320 | ||
| P2093 | author name string | Meng Wang | |
| James M Binley | |||
| Philip E Dawson | |||
| Michael B Zwick | |||
| Richard Jensen | |||
| Emma T Crooks | |||
| Florence M Brunel | |||
| Rosa M F Cardoso | |||
| Josh D Nelson | |||
| Ann Hessell | |||
| P2860 | cites work | Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ | Q21090535 |
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| Antibody vs. HIV in a clash of evolutionary titans | Q24536059 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 | ||
| Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion | Q27641682 | ||
| Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 | Q28236154 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype | Q28646874 | ||
| CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization | Q28646881 | ||
| Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension | Q29547330 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Unraveling hot spots in binding interfaces: progress and challenges | Q29614463 | ||
| Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis | Q29617482 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes | Q29619514 | ||
| Improving antibody affinity by mimicking somatic hypermutation in vitro | Q30724948 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. | Q31143293 | ||
| A general method for greatly improving the affinity of antibodies by using combinatorial libraries | Q33216580 | ||
| Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. | Q33737656 | ||
| Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity | Q33782556 | ||
| Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. | Q33786382 | ||
| Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41 | Q33807129 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. | Q33860721 | ||
| CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range | Q34057663 | ||
| Medicine. The need for a global HIV vaccine enterprise | Q34209402 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D | Q34323863 | ||
| Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope | Q34348303 | ||
| Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody | Q34353296 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses | Q34651668 | ||
| Defining the Protective Antibody Response for HIV-1 | Q35109054 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i | Q35853761 | ||
| Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein | Q35880289 | ||
| Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer | Q36365085 | ||
| The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. | Q36509423 | ||
| Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. | Q36623941 | ||
| Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding | Q36818811 | ||
| Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site | Q36832528 | ||
| Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. | Q37072702 | ||
| A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. | Q39583441 | ||
| Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein | Q39684388 | ||
| Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies | Q39698363 | ||
| Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex | Q39878965 | ||
| Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma | Q40311562 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. | Q40721814 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein | Q40937092 | ||
| Preparation and characterization of human HIV type 1 neutralizing reference sera | Q41332501 | ||
| Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
| The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring | Q44830344 | ||
| Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates | Q45763324 | ||
| Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies | Q53383786 | ||
| Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies | Q57226425 | ||
| In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences | Q67982257 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 4033-4043 | |
| P577 | publication date | 2007-02-07 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 | |
| P478 | volume | 81 |
| Q33547451 | 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms |
| Q36483956 | 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response |
| Q27655865 | A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies |
| Q35566508 | A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens |
| Q34396912 | A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 |
| Q27676864 | A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition |
| Q40220988 | A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles |
| Q31132248 | A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. |
| Q34047445 | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals |
| Q40340474 | Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding |
| Q36337888 | Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. |
| Q46917279 | Adsorption and folding dynamics of MPER of HIV-1 gp41 in the presence of DPC micelle. |
| Q33876210 | Anti-idiotypic monobodies derived from a fibronectin scaffold |
| Q30843874 | Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. |
| Q35660279 | Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q33946158 | Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization |
| Q37547245 | Antigenic properties of the HIV envelope on virions in solution |
| Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
| Q33667654 | Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions |
| Q40145762 | Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope |
| Q35956940 | Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q35689608 | Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Virions |
| Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
| Q38707583 | Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response |
| Q37211421 | Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface |
| Q35012462 | Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L |
| Q37998496 | Candidate Antibody-Based Therapeutics Against HIV-1 |
| Q42114702 | Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q44665312 | Characterization of a trimeric MPER containing HIV-1 gp41 antigen |
| Q34988326 | Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses |
| Q36694111 | Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop |
| Q36747750 | Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens |
| Q21090520 | Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs |
| Q27661588 | Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction |
| Q27657377 | Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications |
| Q38817990 | Dense Array of Spikes on HIV-1 Virion Particles |
| Q40251478 | Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region |
| Q27680089 | Disruption of Helix-Capping Residues 671 and 674 Reveals a Role in HIV-1 Entry for a Specialized Hinge Segment of the Membrane Proximal External Region of gp41 |
| Q27665884 | Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies |
| Q90281664 | Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8 |
| Q34594701 | Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1 |
| Q37730206 | Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes |
| Q43942291 | Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions |
| Q35076987 | Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected |
| Q42287446 | Epitope Specificity of Cross‐Clade Neutralizing Sera from Chinese HIV‐1‐Positive Individuals |
| Q33888559 | Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects |
| Q47547492 | FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS. |
| Q41924154 | Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at its Apex |
| Q28743199 | Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1) |
| Q33508799 | Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region |
| Q30391094 | Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity. |
| Q60913187 | HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design |
| Q39402539 | HIV-1 Virus-Like Particles Bearing Pure Env Trimers Expose Neutralizing Epitopes but Occlude Nonneutralizing Epitopes |
| Q42220533 | HIV-1 hides an Achilles' heel in virion lipids |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q92495399 | HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions |
| Q39617158 | Hepatitis B Virus Surface Antigen Assembly Function Persists when Entire Transmembrane Domains 1 and 3 Are Replaced by a Heterologous Transmembrane Sequence |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q34594905 | Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies |
| Q35592911 | Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual |
| Q34324992 | Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies |
| Q38112585 | Immune response to HIV |
| Q35745442 | Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes |
| Q30353709 | Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. |
| Q35667479 | Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein |
| Q41925820 | Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. |
| Q34937404 | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth |
| Q33725718 | In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 |
| Q34611144 | Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution |
| Q60300903 | Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth |
| Q34517381 | Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. |
| Q36101299 | Insights into the Conformation of the Membrane Proximal Regions Critical to the Trimerization of the HIV-1 gp41 Ectodomain Bound to Dodecyl Phosphocholine Micelles |
| Q34042758 | Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting |
| Q37910841 | Limitations to the structure‐based design of HIV‐1 vaccine immunogens |
| Q35034311 | Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides. |
| Q42284964 | Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers |
| Q53695792 | Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11. |
| Q35904501 | Monoclonal Antibody-Based Candidate Therapeutics Against HIV Type 1 |
| Q38638340 | Multimerized HIV-gp41-derived peptides as fusion inhibitors and vaccines |
| Q39136039 | Multiple antigen peptide mimetics containing gp41 membrane‐proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs |
| Q35826306 | Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane |
| Q57170110 | New approaches to vaccination |
| Q42170072 | Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens |
| Q34273397 | Phages and HIV-1: from display to interplay |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q38348983 | Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. |
| Q33778466 | Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution |
| Q36763346 | Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases. |
| Q36837815 | Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q100295640 | Selection and immune recognition of HIV-1 MPER mimotopes |
| Q39757625 | Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire |
| Q34299053 | Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution |
| Q27680872 | Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 |
| Q36498144 | Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge |
| Q38050485 | Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q27675260 | Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope |
| Q34987048 | Structure-based Vaccine Design in HIV: Blind Men and the Elephant? |
| Q52581587 | The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects |
| Q37789346 | The humoral response to HIV-1: new insights, renewed focus. |
| Q34614862 | The immune response during acute HIV-1 infection: clues for vaccine development |
| Q36384607 | The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation. |
| Q36497712 | The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design |
| Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
| Q40957319 | Trimerization of the HIV Transmembrane Domain in Lipid Bilayers Modulates Broadly Neutralizing Antibody Binding |
| Q59354034 | Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction |
Search more.